一名四十多岁的女性患有复发性 B 细胞淋巴母细胞淋巴瘤，接受了 blinatumomab 治疗，但该药物被证明无效。氯法拉滨挽救治疗使病情完全缓解，她接受了来自 HLA 匹配的同胞捐献者的同种异体干细胞移植 (allo-SCT)。然而，异基因SCT仅4个月后，她的疾病就复发了。进行了三个疗程的供体淋巴细胞输注（DLI）和博纳吐单抗的联合治疗，肿瘤进展在 6 个月内得到了良好的控制，从而导致 HLA 单倍体供体进行了第二次同种异体 SCT。病情持续缓解约一年，但中枢神经系统疾病复发，最终死亡。我们的病例证明了 DLI 和 blinatumomab 联合使用的有效性和安全性。这种组合可能增强了同种异体 T 细胞的移植物抗淋巴瘤效应，而不会引起移植物抗宿主病。© 2023 作者。由巴塞尔 S. Karger AG 出版。

A woman in her forties with relapsed B-cell lymphoblastic lymphoma was treated with blinatumomab, but the drug proved ineffective. Salvage therapy with clofarabine induced a complete remission, and she received an allogeneic stem-cell transplantation (allo-SCT) from an HLA-matched sibling donor. However, her disease relapsed only 4 months after the allo-SCT. Three courses of combination therapy with donor lymphocyte infusion (DLI) and blinatumomab were administered, and the tumor progression was well controlled for 6 months, leading to a second allo-SCT from an HLA-haploidentical donor. The remission was persistent for approximately 1 year, but the disease relapsed in her central nervous system, and she eventually died. Our case demonstrated the efficacy and safety of concomitant use of DLI and blinatumomab. This combination presumably enhanced a graft-versus-lymphoma effect of allogeneic T-cells without provoking graft-versus-host disease.© 2023 The Author(s). Published by S. Karger AG, Basel.